Company intelligence / Profile preview

Aceso Life Science Holding

Haverhill, UK

Ownership: Private
Development stage: Other

Overview

Early-stage joint venture developing stem cell-based therapies for diabetes and liver diseases. The company aims to replace lost insulin-producing islet cells with functional cells differentiated from pluripotent stem cells, offering a potentially curative alternative to insulin injection therapy. Early test results are described as encouraging.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Stem cell therapyCell-based therapyAntibody
Industry: Biotech

Partnerships

Promethera Biosciences (cell-based therapy pipeline partner)Co-High Investment Management Limited (joint venture partner, 49% equity stake)

Beyond the preview

Go deeper on Aceso Life Science Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aceso Life Science Holding.

Explore the full profile